Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kotra Industries BhdXKLS:0002 +1.33%83 Debt-to-Equity is 0.08 as of Mar. 2026, which is 20% below its 10-year median of 0.10. GuruFocus rates XKLS:0002 with a GF Score™ of 83/100 and a GF Value™ of RM4.35 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 815 Drug Manufacturers companies, Kotra Industries Bhd ranks better than 75.83% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kotra Industries Bhd's Debt-to-Equity or its related term are showing as below:
XKLS:0002'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.1 Max: 0.74
Current: 0.08
During the past 13 years, the highest Debt-to-Equity Ratio of Kotra Industries Bhd was 0.74. The lowest was 0.00. And the median was 0.10.
XKLS:0002's Debt-to-Equity is ranked better than 75.83% of 815
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs XKLS:0002: 0.08
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kotra Industries Bhd Debt-to-Equity Related Terms
Kotra Industries Bhd Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Kotra Industries Bhd's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0002 vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kotra Industries Bhd's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kotra Industries Bhd Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kotra Industries Bhd's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kotra Industries Bhd's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kotra Industries Bhd (XKLS:0002) has a Debt-to-Equity of 0.08 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kotra Industries Bhd and its competitors. This is 20% below median its historical median of 0.10. According to the industry distribution chart, Kotra Industries Bhd ranks #197 out of 815 companies in the Drug Manufacturers industry, placing it in the top 24.2%.
Is Kotra Industries Bhd's Debt-to-Equity too high?
Kotra Industries Bhd's current Debt-to-Equity of 0.08 is 20% below median its 10-year median of 0.10. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Kotra Industries Bhd's value of 0.08 is 71.4% below this industry median. Based on the distribution chart, Kotra Industries Bhd ranks #197 out of 815 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kotra Industries Bhd has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kotra Industries Bhd's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kotra Industries Bhd ranks #197 out of 815 companies for Debt-to-Equity. This places Kotra Industries Bhd in the top 24% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.28. Kotra Industries Bhd's value of 0.08 is 71.4% below this benchmark. While the company's 10-year median is 0.10 vs. the industry median of 0.28, Kotra Industries Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kotra Industries Bhd's current Debt-to-Equity of 0.08 is 71.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kotra Industries Bhd and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kotra Industries Bhd's current Debt-to-Equity is 0.08, which is 20% below median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kotra Industries Bhd stock overvalued right now?
Based on GuruFocus' analysis, Kotra Industries Bhd (XKLS:0002) is currently considered Modestly Undervalued. The stock's GF Value™ is RM4.35, compared to a current price of RM3.80 — trading 12.6% below its estimated fair value. The current Debt-to-Equity is 0.08, which is 20% below median its 10-year median of 0.10 and 71.4% below the Drug Manufacturers industry median of 0.28. Kotra Industries Bhd's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kotra Industries Bhd (XKLS:0002), the current Debt-to-Equity is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kotra Industries Bhd (XKLS:0002) Overvalued in 2026?
Based on GuruFocus' analysis, Kotra Industries Bhd stock appears to be undervalued.
The current stock price of RM3.80 is trading 12.6% below its estimated GF Value™ of RM4.35.
GuruFocus considers Kotra Industries Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0002:
Debt-to-Equity: 0.08 (20% below median its 10-year median of 0.10)
GF Value™: RM4.35 vs. price of RM3.80 (12.6% below fair value)
Industry Position: 71.4% below the Drug Manufacturers median (#197 of 815)
No single metric tells the full story. See the XKLS:0002 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kotra Industries Bhd is a Malaysian pharmaceutical company engaged in the development, manufacturing, and supply of pharmaceutical and healthcare products supporting all life stages. Its portfolio includes life-saving medicines, OTC supplements, and nutrition products. The Group markets three core brands: Appeton, offering health supplements and nutrition across all age groups; Vaxcel, providing injectable medicines for infectious diseases, kidney care, and gastroenterology; and Axcel, specializing in oral and topical medicines for paediatrics, dermatology, and infectious diseases. The company operates in Malaysia and overseas, with the majority of revenue derived from Malaysia.
83GF Score
Get the complete analysis for XKLS:0002
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0002 has been successfully added to your 
